A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants
Latest Information Update: 28 Nov 2022
At a glance
- Drugs Clarithromycin (Primary) ; Orforglipron (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Nov 2022 Status changed from active, no longer recruiting to completed.
- 19 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2022 Status changed from not yet recruiting to recruiting.